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Association of Intraocular Pressure With Human
Immunodeficiency Virus
MATTHEW T. YOUNG, RAKHI T. MELVANI, FARAAZ A. KHAN, PUNEET S. BRAICH, AND SURBHI BANSAL
 PURPOSE: Prior studies have shown an association
between human immunodeficiency virus (HIV) and
reduced intraocular pressures (IOP). The purpose of
this study was to determine if patients with HIV on high-
ly active antiretroviral therapy (HAART) had any differ-
ence in their IOP compared with patients without HIV or
with HIV who are not on HAART.
 DESIGN: Retrospective cross-sectional study.
 METHODS: We included 400 patients fromour academic
eye center between 2000 and 2016. Group 1 (G1)
consisted of patients with HIV on HAART (n [ 176),
Group 2 (G2) consisted of patients with HIV who were
not on HAART (n [ 48), and Group 3 (G3) consisted
of controls without HIV (n[ 176). An analysis of vari-
ance (ANOVA) was performed to compare mean IOP
values. Multivariate linear and logistic regression models
were performed to assess factors impacting IOP. Differ-
ence in IOP was the primary outcome being measured.
 RESULTS: The mean IOPs in mm Hg were 13.7 ± 5.1
(G1), 13.1 ± 3.6 (G2), and 17.3 ± 3.8 (G3), P< .01.
In regression modeling, having a CD4 count £700 cells/
mm3 contributed to a 2.1 mm Hg decrease in IOP.
Patients with HIV were 7 times more likely to have an
IOP £10 mm Hg, and patients with a CD4 count £700
cells/mm3 were 13 times more likely to have an IOP
£10 mm Hg.
 CONCLUSIONS: Absolute CD4 counts may play a role
in IOP fluctuations. This association was found in
patients with HIV regardless of whether patients were
on HAART. (Am J Ophthalmol 2017;176:203–209.
 2017 Elsevier Inc. All rights reserved.)
A
S OF 2012, THE CENTERS FOR DISEASE CONTROLAND
Prevention (CDC) estimates that 1.2 million peo-
ple in the United States are living with human
immunodeficiency virus (HIV).1 Estimates of prevalence
for all of North America and Western and Central Europe
elevate this number to 2.4 million individuals.2 About 36%
of those with HIV in the United States are currently
receiving treatment, and 30% are successfully keeping their
disease under control.1 Even with improved education and
screening for HIV, as well as improvements in medical
therapy, these estimates reveal the continued problem of
suboptimal therapy for HIV, which is compounded by
lack of access to health care and low health literacy.3–5
Modern treatment for HIV infection involves the use of
multiple combinations of available antiretroviral therapy
(ART), and the current standard of care is for patients to
be treated with at least 3 of these medications, termed
highly active antiretroviral therapy (HAART). These
medications have dramatically altered the prognosis of
the disease, and although HIV was once considered a fatal
diagnosis, it is now treated as a chronic condition with
continued improvement to life expectancy.2 This change
presents new challenges for healthcare providers as we
continue to learn how to manage comorbid conditions
in this population.
It is estimated that 50%–70% of HIV-positive patients
will develop some type of ocular complication.6 When
comorbid noninfectious ocular conditions are evaluated,
one important area of interest is the diagnosis and treat-
ment of glaucoma, as it has been posited that patients
with HIV may have lower intraocular pressure (IOP).
Arevalo and associates7 explored this area of study by
evaluating IOP in patients with HIV both with and
without cytomegalovirus (CMV) retinitis. They compared
these populations to a control group without HIV and
concluded that patients with HIV had a statistically signif-
icantly lower IOP compared with controls. A study by
Banker and associates8 evaluated aqueous humor dynamics
in patients with and without CMV retinitis. They found
that HIV was associated with lower aqueous flow rates vs
controls independent of CMV status. They concluded
from this that the cause of lower IOP in HIV-infected indi-
viduals may be related to decreased aqueous production
rather than an increase in outflow. Hsu and associates9
used reverse-transcriptase polymerase chain reaction
(PCR) to measure HIV viral load in plasma and aqueous
humor of acquired immunodeficiency syndrome patients
with ocular manifestations including CMV retinitis and
HIV retinopathy. They noted decreased HIV virus levels
in the aqueous in these individuals after initiation of
HAART and recovery of T-cell cluster of differentiation
4 (CD4) counts.
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The association between medications used in patients
with HIV and changes in IOP is also under investigation.
For instance, cidofovir is now a well-documented cause of
ocular hypotony.10,11 Additionally, Park and associates12
performed a retrospective study of IOP in HIV-positive
patients on HAART vs controls, and Kozak and associ-
ates13 performed a longitudinal study of the same relation-
ship. Both groups noted an association between beginning
HAART therapy and subsequent normalization of IOP.
Although Park and associates did not find an association
between CD4 count or viral load and IOP, Kozak and asso-
ciates noted that both a reduction in T-lymphocyte count
and immune recovery defined by a sustained rise in CD4
count were associated with a decrease and increase in
IOP, respectively.
The purpose of this study was to evaluate differences in
IOP between patients with HIV on HAART, patients
with HIV not on HAART, and patients without HIV.
To the best of our knowledge, no previous studies have
directly compared IOP in HIV-positive patients both on
and off HAART therapy. As mentioned previously, only
about a third of patients with HIV in the United States
are receiving treatment,1 providing opportunity to
compare IOP in patients on or off HAART. By directly
comparing these populations, we can gain a better under-
standing of the underlying etiology of decreased IOP in
these patients. Our secondary aim was to understand
what clinical and demographic factors contribute to low
IOP readings.
METHODS
THIS WAS A RETROSPECTIVE OBSERVATIONAL STUDY ON
patients with a diagnosis of HIV on or off HAART ther-
apy compared with those without HIV who were treated
by the ophthalmology department at a tertiary care aca-
demic center from January 2000 to March 2016. Patients
were divided into 1 of 3 groups: Group 1 (G1), patients
diagnosed with HIV and on HAART; Group 2 (G2), pa-
tients with HIV but not on HAART; and Group 3 (G3),
patients not diagnosed with HIV and therefore not on
HAART. The study was conducted in accordance with
the Declaration of Helsinki, and ethical considerations
were approved by the institutional review board at the
Virginia Commonwealth University health system. This
study was approved to be performed as a retrospective
study for all groups.
Reasons for patients with HIV not being on HAART
included noncompliance, a recent diagnosis of HIV,
patients taking time to establish care with an infectious dis-
ease provider, or refusal to begin therapy. G3 consisted of
patients without the diagnosis of HIV evaluated in Virginia
Commonwealth University’s comprehensive eye clinic but
matched for age, race, and sex to G1.
HIV diagnosis was based on having an evaluation by an
infectious disease specialist at our academic center who
documented this diagnosis after positive serum test results
of anti-HIV antibodies using enzyme-linked immunosor-
bent assay followed by confirmatory testing with Western
blot. A practice pattern in our ophthalmology department
is to record the viral load and absolute CD4 count for all
patients diagnosed with HIV, allowing monitoring of
patients who are at risk for ocular opportunistic infections.
We also perform amedical reconciliation via the electronic
health record and paper chart to verify which systemic
medications patients take. This allowed us to verify which
patients were on HAART. Further, patients are questioned
about compliance to medication. We also noted demo-
graphic data such as age, sex, race, IOP, and family history
of glaucoma. IOP measurements were taken by Goldmann
applanation tonometry for all groups. Our medical center’s
laboratory labels a serum sample to have an undetectable
viral load if the count is <20 copies of HIV RNA particles
per mL.
Exclusion criteria consisted of factors that may alter IOP
in significant ways. This encompassed a diagnosis of glau-
coma, treatment with antiglaucoma medications, active
uveitis, prior retinal detachment or retinal hole, history
of CMV retinitis, carotid stenosis >70%, anti–vascular
endothelial growth factor injection therapy, systemic car-
bonic anhydrase inhibitor use, general anesthesia within
past 4 weeks prior to IOP measurement, and cannabis
use. Exclusion criteria were applied to all 3 groups. A total
of 303 potential participants for G1 and G2 were initially
screened based solely on having HIV, and 79 participants
were excluded based on inclusion and exclusion criteria.
This left 176 participants for G1 and 48 for G2. Of those
excluded, 42 had a diagnosis of either glaucoma, glaucoma
suspect, or ocular hypertension or were on IOP-lowering
medication.
Statistical analysis included comparisons of demo-
graphic and clinical data to observe differences among
groups. Categorical variables were compared by x2 tests
for proportions, and by ANOVA for normally distributed
continuous variables and the Kruskal-Wallis test for
nonparametric continuous variables. A linear regression
model was performed whereby the dependent variable
was IOP in the right eye. In this way all patients contrib-
uted 1 eye to the analysis. The independent variables
were age, race (white, black, Hispanic, or other), sex,
CD4 count (either <_700 cells/mm3 or >700 cells/mm3),
viral load (undetectable to 10 000, 10 001–100 000, or
over 100 000 HIV RNA/mL), group association (G1,
G2, or G3), and family history of glaucoma. For the pur-
pose of statistical analysis we assigned a value of 0 for an
undetectable viral load. A binary logistic regression model
was also performed to determine which factors contributed
to a low IOP. In this model the dependent variable was
having an IOP <_10 (yes/no) in the right eye, which pro-
vided estimates of odds ratios (ORs). The ORs and 95%
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confidence intervals (CIs) were obtained by maximum
likelihood estimations, and P values< .05 were considered
statistically significant. A value of <_10 mm Hg was chosen
for the IOP, as this was thought to best represent normal
episcleral venous pressure, although past studies have
shown some variation in this range.14 The independent
variables were age, race (white, black, Hispanic, or other),
sex, CD4 count (either <_700 cells/mm3 or >700 cells/
mm3), viral load (undetectable to 10 000, 10 001–100
000, or over 100 000 HIV RNA/mL), group association
(G1, G2, or G3), and family history of glaucoma. In
both regression models, a backward selection technique
was used to eliminate covariates that did not contribute
significantly to the fit of the model. All statistical analysis
was done with SAS 9.3 (2011; SAS Institute Inc, Cary,
North Carolina, USA).
RESULTS
THERE WAS NO SIGNIFICANT DIFFERENCE IN THE AGE,
race, sex, or family history of glaucoma among the groups
(Table 1). There were significantly more white patients in
G2 (27%) compared with G1 (14%) and G3 (14%),
P < .05. Conversely, there were significantly more black
patients in G1 and G3 compared with G2 (Table 1).
Patients in G3 had the highest absolute CD4 count, which
was significantly higher than G1 and G2. Furthermore, G1
also had a significantly higher value compared with G2 (P
< .01). Only 67 patients in G3 (38%) had a CD4 level
available for comparison because they were concomitantly
receiving chemotherapy from the hematology/oncology
service and required serum work to monitor their leuko-
cyte and related immune parameters. For illustration pur-
poses this subgroup among the controls was labeled as 3B
to reflect treatment by the outpatient hematology/
oncology service at our academic center. These patients
were on a wide variety of chemotherapeutic agents, and
a total of 12 patients (18%) were on T-cell inhibitors
and 18 patients (27%) were on alkylating agents. G2
had a significantly higher viral load compared with G1
(P < .01). The median value for viral load for G1 was
0 (undetectable), while the median value for G2 was 12
000 HIV RNA/mL. The first 2 groups had high outliers,
which skewed their distribution. The range for viral load
TABLE 1. Study Subjects’ Demographic and Clinical Information
Group 1: HIV on
HAART (N¼176)
Group 2: HIV Not on
HAART (N ¼ 48)
Group 3A: Without HIV
(N ¼ 109)
Group 3B: Without HIV,
Hem/Onca (N ¼ 67) P Value
Age (mean 6 SD) 53.5 6 7.4 years 52.1 6 9.6 years 53.8 6 7.9 years 54.1 6 9.4 years .38
Race
Non-Hispanic white 24 (14%) 13 (27%) 19 (17%) 5 (21%) .03
Non-Hispanic black 142 (81%) 32 (67%) 86 (79%) 56 (84%) .04
Hispanic 5 (3%) 1 (2%) 3 (3%) 2 (3%) .88
Other 5 (3%) 2 (4%) 4 (4%) 1 (1%) .61
Sex
Male 128 (73%) 33 (69%) 79 (72%) 49 (73%) .59
Female 41 (22%) 15 (31%) 30 (28%) 18 (27%) .26
Absolute CD4 count
(mean 6 SD)
604.3 6 211.4 cells/mm3 551.6 6 270.8 cells/mm3 - 1084.6 6 158.1 cells/mm3 <.01b
Viral load (mean 6 SD) 5926.7 6 24895.4
HIV RNA/mL
40479 6 103603.3
HIV RNA/mL
- - <.01
Undetectable viral load 96 (55%)
IOP right eye (mean 6 SD) 13.7 6 5.1 13.1 6 3.6 17.1 6 3.2 17.3 6 3.8 <.01c
IOP left eye (mean 6 SD) 13.3 6 5.3 13.3 6 3.8 17.0 6 3.3 16.9 6 4.3 <.01c
Family history of glaucoma 31 (18%) 7 (15%) 16 (12%) 6 (9%) .11
HAART ¼ highly active antiretroviral therapy; Hem/Onc ¼ Hematology/Oncology; HIV ¼ human immunodeficiency virus; IOP ¼ intraocular
pressure; RNA ¼ ribonucleic were a subset of patients in Group 3 who were treated by the acid; SD ¼ standard deviation.
Note: Actual percentages may not add up to 100% owing to rounding to the nearest whole number.
aSubset of patients in Group 3 who were treated by the Hematology/Oncology service and who therefore had testing of immune parameters,
which the remainder of the control group did not.
bPost hoc analysis of variance using Tukey’smethod indicated that there were significant differences between themeanCD4 values between
each of the groups.
cPost hoc analysis of variance using Tukey’s method indicated that there was no difference in the mean IOP values between Groups 1 and 2
or Groups 3A and 3B. However, Groups 3A and 3B were both significantly different compared to each Group 1 and 2. Collapsing Group 3A and
3B into a single groups yields the same results.
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from G1 was undetectable (0) to 220 000 HIV RNA/mL,
while the range for G2 was 258 to 424 000 HIV RNA/
mL.More than half of G1 had undetectable viral loads. Pa-
tients without HIV had significantly higher IOP compared
with patients with HIV (P < .01). Among patients with
HIV, being on HAART did not significantly change IOP
values. The range of IOP values for all eyes was 7–
22 mm Hg (G1), 6–22 mm Hg (G2), and 9–23 mm Hg
(G3). The IOP was not significantly different in right
eyes compared with left eyes for any group. The distribu-
tion of all eyes with an IOP <_10 mm Hg varied across
groups (Figure 1). Among the 352 eyes in G1, 109 had
an IOP <_10 mm Hg (31%), which was significantly higher
than the 22% (21/96) and 16% (55/352) for G2 and G3,
respectively, P < .01. G2 and G3 were not significantly
different from each other. This figure amalgamates Groups
3A and 3B because the proportion from each subgroup was
similar (15% for 3A vs 16% for 3B) and did not change the
overall significance of the comparison.
The only variables significantly affecting the linear
regression model (dependent variable being IOP in the
right eye) was the CD4 count. Compared with patients
with an absolute CD4 count >700 cells/mm3, those with
<_700 cells/mm3 contributed to a 2.1 mm Hg decrease in
the intraocular pressure, P < .01. The adjusted R2 value
for this model was 0.19.
The only variables significantly affecting the logistic
regression model for low IOP in the right eye were CD4
count, group association, and male sex (Table 2). Men
were at a 3-fold higher odds of having an IOP <_10 mm
Hg compared with women. Compared with patients
without HIV, those with HIV, whether or not they took
HAART, had roughly a 7-fold higher odds of having a
low IOP. The greatest impact was from the CD4 count.
Compared with patients with >700 CD4 cells/mm3, those
with <_700 cells/mm3 have more than a 13-fold higher odds
of having a low intraocular pressure. The Nagelkerke R2
31%
22%
16%
0%
5%
10%
15%
20%
25%
30%
35%
HIV on HAART HIV not on HAART Controls
Proportion of All Eyes with Low IOP
FIGURE 1. Graph showing the distribution of all eyes with intraocular pressure (IOP) £10 mmHg. The proportion among Group 1
(patients with human immunodeficiency virus [HIV] on highly active antiretroviral therapy [HAART]) is significantly higher than
both Group 2 (patients with HIV not on HAART) and Group 3 (age- and sex-matched controls without HIV), P< .01. However,
Group 2 and Group 3 are not significantly different from each other.
TABLE 2. Factors Impacting Low Intraocular Pressure
Values in the Multivariate Logistic Regression Model
Variable Odds Ratio (95% CI) P Value
Sex
Female -
Male 3.0 (2.1–4.2) .03
Group association
Group 3 -
Group 2 6.9 (3.9–8.7) <.01
Group 1 7.3 (4.0–9.2) <.01
Absolute CD4 count
>700 cells/mm3 -
<_700 cells/mm3 13.4 (10.4–17.5) <.01
CI ¼ confidence interval.
Nagelkerke R2 ¼ 0.46 for this model.
An intraocular pressure of <_10 via applanation was considered
low for the purposes of this model.
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value for this model was 0.46. Figure 2 demonstrates the
distribution of patients with and IOP <_10 mm Hg who
also have a CD4 count <_700 cells/mm3.
DISCUSSION
PRIOR STUDIES HAVE DEMONSTRATED AN ASSOCIATION
between positive HIV status and decreased IOP. Addition-
ally, it has been hypothesized that immune recovery is asso-
ciated with normalization of IOP compared with controls
without HIV. This study was unique in that it allowed for
a direct comparison of patients with HIV on or off
HAART.
A greater proportion of patients with HIV both on and
off HAART had an IOP <_10 mm Hg vs controls. In the
linear regression model, a CD4 count of <700 cells/mm3
contributed to a 2.1 mm Hg decrease in intraocular pres-
sure. The R2 value was only 0.19 in the linear regression
model, indicating that all variables within this model
account for 19% of the variability in IOP. It is worth
noting that CD4 count was the only variable that signifi-
cantly contributed to a reduced IOP in this model.
Although it appears that 81% of the variation could be
accounted for by variables that we have not measured, it
is noteworthy that almost one fifth of the variation can
be accounted for by a single variable. On logistic regres-
sion, low IOP was also associated with male sex; however,
this may be an artifact owing to the disproportionate
number of male subjects represented in the study. Addi-
tionally, patients with HIV were about 7 times more likely
to have an IOP <_10 mm Hg. Patients with a CD4 count
<_700 cells/mm3 were 13 times more likely to have an
IOP <_10 mm Hg. These relationships were independent
of HAART status.
Causes of decreased IOP in patients with HIV are likely
multifactorial, as hypothesized by previous authors. Prior
studies have demonstrated decreased aqueous flow by fluo-
rophotometry in these individuals.8 It has also been sug-
gested that a low-grade cyclitis may contribute to a
lowered IOP,12 which would explain why immune recovery
is associated with a return to values matching those without
HIV. HIV has been detected in aqueous fluid by reverse-
transcriptase PCR; however, it is not clear whether the
presence of the virus within the aqueous directly impacts
IOP.9 CMV retinitis has also specifically been implicated
in lowered IOP and hypotony, which is thought to be
related to increased aqueous flow directly across damaged
retina,8 as well as ciliary body atrophy.12 Administration
of cidofovir for treatment of CMV retinitis is associated
with hypotony10,11; however, in our study patients with
history of CMV retinitis were excluded so as to control
for this. The fact that lower IOP was found among those
with a decreased CD4 count, independent of their
HAART status, is suggestive that either immune
suppression or active HIV infection contributes to lower
IOP, rather than the direct effect of antiretroviral therapy.
58%
62%
16%
G1 with ≤ 700 CD4 cells/mL G2 with ≤ 700 CD4 cells/mL G3 with ≤ 700 CD4 cells/mL
Proportion of Patients with Lower CD4 Count Among those with Low 
IOP  
FIGURE 2. This graph shows the distribution of all eyes with intraocular pressure (IOP) £10 mm Hg and also a CD4 £700 cells/
mm3. The proportion among Group 1 and Group 2 are both significantly higher than Group 3 (P< .01), but not significantly
different from each other. Group 1 (G1)[ patients with human immunodeficiency virus (HIV) on highly active antiretroviral ther-
apy (HAART); Group 2 (G2)[ patients with HIV not on HAART; and Group 3 (G3)[ age- and sex-matched controls without
HIV.
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There were several limitations to this study. This was a
retrospective cross-sectional study, which can limit data
collection owing to missing values and long-term follow-
up. A longitudinal study might provide a more precise rep-
resentation of patients’ IOP and how CD4 count and viral
load may play a role over time. Additionally, the majority
of patients seen in the general eye clinic at our academic
center are black men; therefore the findings may not be
generalizable to all populations. Further studies are needed
to verify the relationship between CD4 count and IOP.
The control group for this study included patients who
were receiving chemotherapy for various types of malig-
nancies by the hematology/oncology service. Although
this provided an opportunity to compare CD4 counts to
those of patients without HIV, it can be argued that the
control group does not represent our study population.
However, when stratifying for these patients in our
descriptive statistical representation, there was no major
differences within controls. Given that CD4 count and
IOP within this group approach previously measured
mean values, the impact this had on skewing our results
is likely minimal. Furthermore, these patients represent a
convenience sample, a commonly used method when
selecting controls.15–17 Another limitation is that
patients with glaucoma or who were diagnosed as
glaucoma suspect were not studied to avoid confounding
variables such as prior or current IOP-lowering therapy.
Before these populations are studied, the correlation
between CD4 count and IOP must become better under-
stood in a healthy population. Further studies of popula-
tions with glaucoma and HIV as comorbid conditions are
needed. Lastly, specific HAART regimens were not stud-
ied. Owing to the variety of HAART regimens our
patients were on, as well as scenarios where HAART reg-
imens had recently been changed prior to their eye exam-
ination, analyzing any specific medication or combination
of medications was beyond the scope of this study.
Although this should not significantly impact our data if
IOP is more directly related to immune recovery, it limits
our ability to identify a specific medication or class of med-
ications that could have an IOP-lowering effect. Further
studies on specific medications or medication classes are
needed.
HAART is a well-established therapy for patients with
HIV, and it has become increasingly important to under-
stand how HIV and antiretroviral therapy affect chronic
medical conditions, including issues related to visual
health. Understanding how IOP is affected both by
HIV and antiretroviral therapy will aid in the manage-
ment of patients with glaucoma and related entities.
Future research on specific medication regimens and
their impact on IOP could be valuable in managing
the visual health in patients with HIV. Additionally, un-
derstanding the association between immune suppression
and IOP may be useful in the development of future
medications designed for treating glaucoma. Further
studies on patients with HIV and decreased CD4 counts
will provide an opportunity to explore this relationship.
Though the literature supporting the link between lower
IOP and HIV continues to grow, further research is
needed on the subpopulation of patients with the diag-
nosis of glaucoma.
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